Introduction
Microdeletion syndromes are defined as a group of clinically recognizable disorders which are characterized by a small (<5Mb) deletion of a chromosomal segment spanning multiple disease genes, each potentially contributing to the phenotype independently [1] . Alongside, the recent explosion in the implementation of genome-wide microarray technology to discover rare, pathogenic genomic rearrangements in a variety of diseases has led to the discovery of numerous microdeletion syndromes [2] . These microdeletions are associated with extensive phenotypic heterogeneity and incomplete penetrance. The recurrent microdeletion had been reported to underpin diverse phenotypes, including intellectual disability, autism, epilepsy and neuropsychiatric disorders [2] .
The Contiguous Gene syndromes in 1986 defined by Schmickel was the first to give rise to the 'microdeletion syndromes' which involved the deletion of a contiguous stretch of DNA, including multiple genes, on a chromosome [3] .These syndromes are clinically recognized with distinct physical, behavioural, and mental characteristics and often involve some individual features that can be inherited in a Mendelian fashion [3] .
The common microdeletion syndromes that have been reported till date are Smith-Magenis Syndrome, Miller-Dieker Syndrome, Prader-Willi Syndrome, Angelman Syndrome, Velocardiofacial Syndrome and DiGeorge Syndrome and Williams Syndrome [3] , which has been summarized in Table 1 .
II.
Microdeletion Syndromes
Angelman Syndrome
Angelman Syndrome (AS) was first described by Dr. Harry Angelman in 1965 [24] . It was characterized by developmental delay, absent speech, ataxic gait, seizures and a distinctive behavioural phenotype with excitability and paroxysms of laughter [24] . The incidence has been reported to be 1/12,000 to 1/20,000 [25, 26] . AS is caused by disruption of the function of the maternally inherited ubiquitin-protein ligase E3A (UBE3A) gene within the 15q11-q13 region [27] [28] [29] [30] [31] . This region spans approximately 120 kb of genomic DNA and contains 16 exons with coding region of 60 kb [24] .
In normal neurons, UBE3A is transcriptionally inactivated on the paternally derived allele of chromosome 15 and is active only on the maternally derived allele [24] . The syndrome occurs due to 4 different mutational mechanisms affecting the maternally derived chromosome 15: intragenic mutation, deletion of the gene, paternal UPD with absence of maternal chromosome 15 and a defect in the imprinting center that controls UBE3A transcription [24] . In imprinting inheritance, offspring of carrier mothers are theoretically at 50% risk of having AS [31] .
22q11.2 Deletion syndrome
Di George/ VeloCardio Facial Syndrome (DG/VCFS) are caused by a deletion at 22q11.2 [3] . DG/VCFS has been reported as the most common microdeletion syndrome, with an estimated incidence of 1 in 4000 births [3] . Tomita-Mitchell and colleagues reported that 22q11.2 DS which is also known as DiGeorge syndrome type 1 (DGS1) is the most prevalent inheritable genetic deletion syndrome [32] . The common features of this syndrome are congenital heart disease, cleft palate, velopharyngeal insufficiency with hypernasal speech, hypocalcaemia, dysmorphic facial features and mild to moderate mental retardation, with a high variability in the number and severity of associated features [33] . Individuals with 22q11.2 DS often experience recurrent infections caused by problems with the immune system, and some develop autoimmune disorders such as rheumatoid arthritis and Graves' disease [34] .
Congenital heart defects are present in approximately 75% of patients with 22q11.2DS and typically constitutes conotruncal malformations such as interrupted aortic arch type B, truncus arteriosus communis, tetralogy of Fallot and pulmonary atresia with ventricular septal defect [35] . Although psychotic disorders among 22q11.2DS patients is high with about 1 in every 5 patients, non psychotic conditions has also been reported to be more prevalent [36] . Van Engelen et al., (2010) also reported that individuals with 22q11.2DS have a 50% chance of transmitting the deletion to his or her offspring.
22q11.2 deletion syndrome is a contiguous gene deletion syndrome inherited in an autosomal dominant manner [37] . About 93% of probands have a de novo deletion of 22q11.2 and 7% have inherited the 22q11.2 deletion from a parent [37, 38] . Meanwhile, offspring of affected individuals have a 50% chance of inheriting the 22q11.2 deletion. The deletion occurs most often as a random event during the formation of reproductive cells or in early foetal development. Affected individuals usually do not have any history of the disorder in their family, though they can pass the condition to their children. In about 10% of cases, a person with this condition inherits the deletion in chromosome 22 from a parent. In inherited cases, other family members may be affected as well.
One of the key genes, TBX1, encodes a T-box transcription factor, which is known to have an essential role in early vertebrate development. TBX1 has been suggested as a candidate gene for del22q11.2 syndrome, TBX1 is a recently described member of the T-box gene family that has been conserved throughout metazoan evolution. Other T-box proteins have been identified in various species that have a range of roles in early vertebrate development and aspects of mesoderm specification, including heart and limb development. Three genes from this family have been associated with dominant human disorders. Mutations in TBX3 result in ulnarmammary syndrome. TBX5 mutations cause Holt-Oram syndrome. Mutations in TBX22 lead to cleft palate with ankyloglossia. Therefore, we conclude that TBX1 would be a major genetic determinant of del22q11.2 syndrome in human beings.
Williams-Beuren Syndrome
Williams-Beuren syndrome (WBS) is a neurodevelopmental disorder involving facial appearance characteristics, supravalvular aortic stenosis and mental retardation [39] . WBS has also been presented with a wide collection of symptoms affecting blood vessels, growth, intelligence, and behaviour [39] . Children with this condition have distinctive facial features, a hoarse voice associated with growth, mental retardation and an overfriendly personality; hyperacusis, infantile hypercalcemia, prematurely wrinkled skin are also common symptoms [40] .
WBS has been reported to be in 1 in 7,500 live births with no ethnic or sex preference [41, 42] and is caused by a hemizygous contiguous gene microdeletion at 7q11.23 spanning 28 genes [43] . 90 to 95% of the WBS patients showed 1.55Mb deletion due to mispairing between the centromeric and medial LCR (Low copy repeats) blocks B (Bcen and Bmid) [44] . Meanwhile 5 to 10% of cases showed an ~1.84-Mb deletion spanning the breakpoints within the centromeric and medial LCR blocks A (Acen and Amid) [45] .
The classification of WBS phenotype is largely based on evidences from functional studies of single genes, animal models, and analysis of WBS individuals with atypical deletions [43] . Studies conducted by Antonell and colleagues (2010) concluded that hemizygosity of LIMK1, CLIP2, GTF2IRD1, and GTF2I is associated to the specific WBS cognitive profile and craniofacial features. Meanwhile, another study suggests that reduced BAZ1B protein level has been linked to cardiac, craniofacial, and hypercalcemia defects [46] .
17q21.31 Microdeletion Syndrome
17q21.31 was first reported in 2006 with an estimated prevalence of 1 in 13,000 to 20,000 [47] . The 17q21.31 deletion was reported to occur de novo and the characteristic features include moderate intellectual disability, developmental delay, severe hypotonia, and facial dysmorphisms, especially a long face and tubular or pear-shaped nose [47] . This syndrome also may include epilepsy, anomalies of the central nervous system such as corpus callosum defects and hydrocephalus and congenital abnormalities of heart and kidneys [48] . This microdeletion syndrome is largely due to microtubule-associated protein tau (MAPT) haploinsufficiency which in turn leads to neurodegenerative disorders such as fronto-temporal dementias and progressive supranuclear palsy [48] [49] [50] . 
III. Microdeletion Detection Methods
Chromosome deletion and microdeletion syndromes account for an increasing number of clinically recognizable genetic conditions. New deletion syndromes continue to be characterized and a number of previously described syndromes are being found to be due to chromosomal deletions or microdeletions. Several molecular genetics methods including multiplex ligation-dependent probe amplification (MLPA), fluorescence in situ hybridization (FISH), quantitative fluorescent PCR (QF-PCR) and microarray-based comparative genomic hybridization (arrayCGH) have been well established for prenatal diagnosis of chromosomal abnormalities in clinical labs [51, 52] .
Multiplex Ligation Dependent Probe Amplification
MLPA is a variation of the multiplex polymerase chain reaction that permits multiple targets to be amplified with only a single primer pair. Each of the probes consists of two oligonucleotides which recognise adjacent target sites on the DNA with one of the probe containing the sequence recognised by the forward primer, while the other the sequence recognised by the reverse primer [53] . Only when both probe oligonucleotides are hybridised to their respective targets, can they be ligated into a complete probe. Each complete probe has a unique length, so that its resulting amplicons can be separated and identified by (capillary) electrophoresis [53] .
Fluorescent In Situ Hybridization
FISH technologies are in wide clinical use to diagnose deletion and microdeletion syndromes [54] . Future uses of these technologies will provide prognostic information for patients and their parents, as the genes responsible for the phenotypic aspects of various deletion syndromes are identified [54] . The technique of FISH is based on the same principle as any DNA hybridization method that uses the ability of single-stranded DNA to anneal to complementary DNA [55] . In the case of FISH, the target DNA, which may be metaphase chromosomes, interphase nuclei or tissue sections, is attached to a glass microscope slide [55] . The development of a complete set of unique FISH clones near the junction of subtelomeric sequences of each chromosome arm allowed a targeted analysis of all human telomeres to identify cryptic deletions, duplications, and unbalanced translocations [56] . The advantage of FISH is its improved speed and spatial resolution, labelled probes are stable and can be stored over long periods, and the possibility of detection of multiple targets simultaneously in different colours [55] . Moderate intellectual disability, developmental delay, severe hypotonia, and facial dysmorphisms, especially a long face and tubular or pear-shaped nose
Sequencing
Although the above mentioned testing methods have been proved to be highly reliable, the major limitation remains restricted resolution and limited coverage on the human genome at one time [57, 58] . To overcome these limitations, studies have been focussing on sequencing techniques in detection of microdeletions [59, 60] . With the application of third-generation sequencing system in clinical laboratories, such as Miseq/Illumina and Ion Torrent PGM/Life Technologies, the whole process takes less time with acceptable price [59] . Thus, it is likely that massively parallel sequencing (MPS) will play an increasingly important role in the future development of prenatal screening and diagnosis [59] .
Quantitative Fluorescent PCR
QF-PCR, which is based on the amplification of chromosome-specific DNA short-tandem-repeat (STR) polymorphisms. This technique employs fluorescnt primers to detect peaks on a DNA sequencer . Normal heterozygous subjects are expected to show two peak areas (peaks ratio 1 : 1) for each locus analyzed, while trisomies are visualized either as an extra peak (triallelic) or as a 2 : 1 ratio between the peak areas for two peaks at a given locus . Besides this, recent reports involving large numbers of patients have clearly demonstrated the clinical efficacy of QF-PCR in the detection of aneuploidy [61] [62] [63] .
Microarray-based Comparative Genomic Hybridization
Bejjani and Shaffer [64] described microarray-based comparative genomic hybridization (array CGH) as a revolutionary platform that was recently adopted in the clinical laboratory, which allows a high-resolution evaluation of DNA copy number alterations associated with chromosome abnormalities. Array CGH has many research applications including cancer profiling, gene discovery, and understanding epigenetic modifications and chromatin conformation [64] .
Array CGH is also widely being applied in detection of copy number changes in a resolution of even as low as 1Kb [65] . ISCA (International Standard Cytogenomic Array) Consortium supports the use of array CGH as a first-line test and suggests reserving chromosomal G-banding analysis for specific cases like patients with obvious chromosomal syndromes such as Down syndrome and family history of chromosomal rearrangements [65] . The high resolution afforded by array CGH has been used to define candidate regions for putative genes responsible for human genetic diseases [64] . Vissers and colleagues [66] proved this by hybridizing cell lines from two individuals with CHARGE syndrome onto a genome-wide array with a 1-Mb resolution.
The primary advantage of array CGH over fluorescence in situ hybridization (FISH) is its ability to detect DNA copy changes such as deletions, duplications, or amplifications, simultaneously at multiple loci in a genome [64] .
IV. Conclusion
Although one or few genes have been reported to have a greater impact, it is the cumulative effect of the imbalance of several other genes in the deletion that determines the overall phenotype and the presence of additional genetic and environmental modifiers may also contribute to the variability in the observed phenotypes of these syndromes. Adding to this, early diagnosis and comprehensive care of these patients in recent years has increased radically thus enabling a better insight into these eminent syndromes. This further facilitates an accurate understanding of the genome and potential gene therapies, which then leads towards the detection of mutations with important role in various areas of genetic diagnosis including pre-implantation genetic diagnosis (PGD), prenatal diagnosis (PND), pre-symptomatic testing, conformational diagnosis and forensic/identity testing [67] . Furthermore, the application of array CGH has created a paradigm shift in genetics that has moved the description and discovery of genetic conditions from the "phenotype-first" approach, in which patients exhibiting similar clinical features are identified prior to the discovery of an underlying aetiology, to a "genotype-first" approach, in which a collection of individuals with similar copy-number imbalances can be examined for common clinical features [68] . The importance of cytogenetics in these syndromes has paved way to the exploration into the developmental pathways in a functional approach which further aids in identification of many new microdeletion syndromes.
